Telomir Pharmaceuticals Stock Rises 2.3% Amid Analyst Ratings Changes

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) experienced a significant uptick of 2.3% during mid-day trading on Wednesday, reaching a high of $1.33 before settling at $1.32. Approximately 179,746 shares changed hands, marking a notable decline of 72% from the average daily trading volume of 645,422 shares. The stock had closed at $1.29 prior to this increase.

Analyst Ratings and Company Performance

On the same day, Weiss Ratings reiterated a “sell (e+)” rating for Telomir Pharmaceuticals in a research report issued on October 8, 2023. The company’s stock has garnered mixed reviews from analysts, with one investment analyst recommending a Strong Buy, another issuing a Buy rating, and a third suggesting a Sell rating. According to data from MarketBeat.com, Telomir currently holds an average rating of “Moderate Buy” with a consensus price target set at $15.00.

The company last reported its quarterly earnings on November 10, 2023, announcing an earnings per share (EPS) of ($0.03). This result exceeded analysts’ expectations, which had anticipated an EPS of ($0.07), surpassing the estimate by $0.04. Analysts project that Telomir Pharmaceuticals will post an EPS of ($0.40) for the current fiscal year.

Institutional Investor Activity

Recent changes in institutional investor positions have also influenced Telomir’s stock. Bank of America Corp DE significantly increased its stake in the company by 283.9% during the fourth quarter, acquiring a total of 14,713 shares valued at $61,000. This followed the purchase of an additional 10,880 shares in the same period.

Other notable institutional transactions include Nuveen LLC, which acquired a new stake in Telomir valued at approximately $81,000 in the first quarter, and HighTower Advisors LLC, which purchased shares worth about $139,000 during the same timeframe. Additionally, Y Intercept Hong Kong Ltd and Marshall Wace LLP entered into new positions in the second quarter, valued at around $81,000 and $95,000 respectively.

Telomir Pharmaceuticals operates as a pre-clinical-stage pharmaceutical company, focusing on the development and commercialization of therapeutic treatments for human stem cells. The company is advancing TELOMIR-1, an innovative small molecule designed to serve as an oral therapeutic intervention for age-related inflammatory conditions, including hemochromatosis and osteoarthritis, as well as health concerns arising from post-chemotherapy treatments.

This increase in stock value and the mixed analyst ratings reflect ongoing interest and investment in Telomir Pharmaceuticals as it navigates its path in the pharmaceutical landscape.